A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2009
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2007 New trial record.